Marc Ditmarsch
Corporate Officer/Principal presso FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Patrimonio netto: - $ in data 31/05/2024
Posizioni attive di Marc Ditmarsch
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 01/08/2022 | - |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Corporate Officer/Principal | 01/01/2020 | - |
| Direttore operativo | 01/01/2020 | - |
Storia della carriera di Marc Ditmarsch
Precedenti posizioni note di Marc Ditmarsch
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| AstraZeneca BV | Direttore Tecnico/Scientifico/R&S | 01/01/2014 | 01/01/2016 |
Formazione di Marc Ditmarsch
| Vrije Universiteit Amsterdam | Doctorate Degree |
Statistiche
Distribuzione geografica
| Paesi Bassi | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
| AstraZeneca BV | |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
- Borsa valori
- Insiders
- Marc Ditmarsch
- Esperienza
